分类: 光学 >> 量子光学 提交时间: 2023-02-19
摘要: We consider using the system's optical imaging process with convolutional neural networks (CNNs) to solve the snapshot hyperspectral imaging reconstruction problem, which uses a dual-camera system to capture the three-dimensional hyperspectral images (HSIs) in a compressed way. Various methods using CNNs have been developed in recent years to reconstruct HSIs, but most of the supervised deep learning methods aimed to fit a brute-force mapping relationship between the captured compressed image and standard HSIs. Thus, the learned mapping would be invalid when the observation data deviate from the training data. Especially, we usually don't have ground truth in real-life scenarios. In this paper, we present a self-supervised dual-camera equipment with an untrained physics-informed CNNs framework. Extensive simulation and experimental results show that our method without training can be adapted to a wide imaging environment with good performance. Furthermore, compared with the training-based methods, our system can be constantly fine-tuned and self-improved in real-life scenarios.
分类: 物理学 >> 普通物理:统计和量子力学,量子信息等 提交时间: 2017-11-17
摘要: The structural superposition of DPP-IV complex with Alogliptin and Linagliptin displayed a similar binding mode. The butynyl of Linagliptin and cyanobenzyl of Alogliptin occupy the S1 pocket which therefore could be mutually switched. Thus a pharmacophore hybridization of Alogliptin was initiated and led to a novel DPP-IV inhibitor 61. Though it did not exhibit desired activity (IC50= 0.2 礛), the butynyl compound acts as a lead compound triggered a following structural optimization. A novel series of potent DPP-IV inhibitors represented by compound 77 (IC50= 0.36 nM) were obtained with a robust pharmacokinetic profile and better in vitro and in vivo efficacy than Alogliptin.
分类: 生物学 >> 生态学 提交时间: 2017-11-17
摘要: Followed pharmacological evaluation exposed an extensive hepatic first pass effect within our recently disclosed DPP-IV inhibitors bearing thienopyrimidine scaffold. Through scaffold replacement with pyrrolopyrimidine, compound 1a had substantially improved the metabolic stability (from 6.6% to 65.07%), yet with severely poor absorptive property. Further modification by incorporation with varied substituents and structure conversion yielded both permeable and metabolic stable compounds. The whole pharmacokinetic- property based optimization had succeeded in balancing overall properties and resulted in the compound 1j, that with excellent efficacy to be a potential anti-diabetic candidate.